VEDICINALS®

Indo-German Biotech

VEDICINALS 9®

PRESENTATION

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

Disclaimer : This presentation cannot and does not contain medical advice. The information is provided for general informational and educational purposes only and is not a substitute for professional medical advice. Accordingly, before taking any actions based upon such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical advice.

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

I am here today to make a strong case for nutraceuticals and dietary supplements.

Over the last decade I dedicated my resources and time to the question of why do we have such an incredible healthcare system in the developed world with such a highlife expectancy but with constantly rising numbers of chronic illnesses? (45% of US population as of 2018) One of the driving factors we could find, is our current lifestyle, especially conventional food coming from industrialized agriculture and being processed and refined. Lacking phenolic compounds minerals and other signalling molecules, and on top of that containing an array of disruptive chemicals. My colleagues and I setup several small and large scale organic agricultural projects in order to produce better food and at the same time developed nutraceutical interventions that restore and balance the organisms of people being overly exposed to "modern lifestyle".

In January 2020 Sars Cov2 came in, an additional problem that needed to be solved. We ran many of the pathways that were showing to be disrupted in Covid and Long Covid through extensive databases in order to filter out of 8000 known natural molecules the most promising "multitalented" ones.

In order to have them do their synergistic job of restoring homeostasis, assimilating in the affected cell and organ regions, we had to over come the biggest obstacle, which is well known, BIOAVAILABILITY!

In the following slides I will show you some of the data and the science behind it:

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions



Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

LONG COVID PROTOCOL

BAICALIN	352mg
QUERCETIN	100mg
LUTEOLIN	200mg
RUTIN	736mg
HESPERIDIN	667mg
CURCUMIN	1052mg
EPIGALLOCATECHIN-GALLATE	889mg
PIPERINE	15mg
GLYCYRRHIZIN	505mg

VEDICINALS 9®

Suspension 50 mL

Recommended Dosage :

01 Bottle (50mL) Daily for 28 days or 42 days as directed by your medical professional.

FOR INTERNATIONAL ORDERS,
Click below button

Buy Vedicinals9

www.vedicinals.com

Following dietary supplements have been reported to be beneficial in combination with Vedicinals9®

- VITAMIN C
- VITAMIN D3
- ZINC
- MELATONIN
- OMEGA3
- SULFOROPHANE
- MONOLAURIN

(Please define individual dosages with your health professional)

LONG COVID RECOMMENDATIONS

As hypersensitivity, inflammatory and thrombotic conditions are present in Long Covid Conditions, We advise to check on certain habits and diets.

1. **Try to avoid foods that are high in Histamine.**
   Link : https://www.mastzellaktivierung.info/downloads/foodlist/21_FoodList_EN_alphabetic_withCateg.pdf
2. **Try to eat more fresh unprocessed food.**
3. **Try to eat mostly organic !!!**
4. **Drink plenty of water! (avoid plastic bottles and cans)**
5. **While feeling unwell please do not exaggerate physical activities!**
6. **Avoid mouldy houses !**
7. **Avoid perfumes, scented candles and air fresheners.**

Probiotics

Histamine

Contains following strains:

Bifidobacterium infantis
Bifidobacterium bifidum
Bifidobacterium longum
Lactobacillus salivarius
Lactobacillus plantarum
Bifidobacterium lactis
Bifidobacterium breve

Click below link to view details

https://www.ergomax.de/seeking-health-probiota-histaminx-60-kapseln

Microbiome Labs RestorFlora

Contains following strains:

Saccharomyces boulardii (CNCM-I-1079)
Bacillus clausii (SC-109)
Bacillus subtilis (HU58)
Cellulose, Vegetarian Capsule.

Click below link to view details

https://www.amazon.com/Restorflora-Probiotic-Supplement-50-Capsules/dp/B00NAOSGAE

DISCLAIMER : The Site can not and does not contain medical advice. The information is provided for general informational and educational purposes only and is not a substitute for professional medical advice. Accordingly, before taking any actions based upon such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical advice.

www.vedicinals.com

Copyright : Vedicinals India Private Limited

PHASE - 1 : VIRAL REPLICATION

By targeting the virus structural proteases, blocking a large number of host cell receptors, reducing cell fusion cleavage enzymes and dampen intracellular replication, we obtained very good results during our clinical phase 2 trials.

4. Covid 19 patients CT value (Viral Load RT-PCR)

Intervention	Day 0-5 (Mean ± SEM)	Significance P Value
Standard (S)	1.399±0.092	
Vedicinals9 + Standard (SV9)	1.762±0.1257	*P (0.0221)



Fig 2. Effect of VEDICINALS9 on CT value (Viral Load) of COVID-19 positive patients from day 0 to 5. Data interpret following: comparison of mean difference in CT value per day (Viral Load) from day 0 to 5, when vedicinals9 5000mg adjuvant with standard intervention compared with standard intervention alone. Data represented as change in CT value (Viral Load) levels (Mean ± SEM) in two comparable interventional group (n=62 per group). Significant at *p<0.05, **p<0.01, ***p<0.001, ****P<0.0001 when compared before and after intervention at day 5 both interventional groups. [Unpaired t test with Welch's correction]

1. Cumulative no. of COVID-19 patients turning negative in days (RT-PCR)



Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE -1 : VIRAL REPLICATION			Active Ingredients								
VIRUS STRUCTRAL PROTEASE INHIBITORS			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
01	3C-LIKE PROTEASE	INHIBITORS	✸	✸	✸	✸	✸	✸	✸	✸	✸
02	SPIKE GLYCOPROTEIN	INHIBITORS		✸	✸		✸	✸			✸
03	ENVELOPE GYLCOPROTEIN	INHIBITORS					✸				
04	NUCLEOCAPSID PROTEIN	INHIBITORS					✸				
05	PAPAIN-LIKE PROTEASE	INHIBITORS	✸						✸		
06	RNA-DEPENDENT RNA POLYMERASE	INHIBITORS		✸		✸				✸	✸
07	HELICASE	INHIBITORS				✸	✸				

PHASE -1 : VIRAL REPLICATION			Active Ingredients								
BLOCKING HOST CELL RECEPTORS - BINDING INHIBITORS			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
08	RBD-ACE 2	BINDING INHIBITORS	✸	✸		✸	✸	✸	✸		✸
09	APN + CD 13	BINDING INHIBITORS						✸			
10	DPP4	BINDING INHIBITORS		✸		✸		✸	✸		
11	CD 147	BINDING INHIBITORS	✸					✸	✸	✸	
12	PALS - 1	BINDING INHIBITORS	✸	✸	✸		✸	✸	✸	✸	✸
13	NRP - 1	BINDING INHIBITORS		✸				✸	✸		
14	VIMENTIN	BINDING INHIBITORS	✸	✸	✸			✸	✸		
15	GRP - 78	BINDING INHIBITORS	✸	✸	✸	✸		✸	✸	✸	
16	GP - 41	BINDING INHIBITORS						✸	✸		
17	LIPID RAFTS	INHIBITORS						✸	✸		✸
18	INTEGRIN AVB3	INHIBITORS		✸	✸			✸	✸		

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE -1 : VIRAL REPLICATION			Active Ingredients								
CLEAVAGE/ FUSION ENZYME INHIBITORS			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
19	ENDOCYTOSIS	INHIBITORS	✸	✸		✸		✸	✸		✸
20	TMPRSS - 2	INHIBITORS	✸						✸		✸
21	FURIN	INHIBITORS	✸		✸	✸	✸	✸		✸	
22	TRYPSIN	INHIBITORS	✸	✸	✸	✸	✸	✸	✸		✸
23	CATHGPSIN - 6	INHIBITORS		✸							
24	HEPARAN SULFATE BINDING	INHIBITORS								✸	
25	TYROSINE KINASE	INHIBITORS	✸	✸	✸			✸	✸	✸	
26	SYNCYTIUM / SYNCYTIA FORMATION	INHIBITORS	✸	✸	✸						
27	ALPHA ANTI TRYPSIN	AGONISTS		✸		✸		✸	✸		

PHASE -1 : VIRAL REPLICATION			Active Ingredients								
INTRACELLULAR REPLICATION ANTAGONISTS			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
28	ZINC IONOPHORES			✸					✸		
29	DODH	INHIBITORS	✸	✸	✸			✸		✸	✸
30	CALPAIN	INHIBITORS		✸							

Copyright : Vedicinals India Private Limited

PHASE - 2 : HYPERSENSITIVITY

How To Reduce Mast Cell Activation ?

Mast Cell



Reference :

https://franklincardiovascular.com/do-i-have-mast-cell-activation-syndrome-mcas/

https://openi.nlm.nih.gov/detailedresult?img=PMC3314669_pone.0033805.g002&req=4

https://www.sciencedirect.com/science/article/pii/S0925443910002929

Quercetin

Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in humans.

Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, Katsarou-Katsari A, Antoniou C, Theoharides TC - PloS one (2012)



Luteolin



PHASE - 2 : HYPERSENSITIVITY			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
31	ANTI – HYSTAMINES + H1	BLOCKERS	✸	✸	✸		✸	✸	✸		✸
32	MAST CELL	STABILIZERS	✸	✸	✸	✸	✸	✸	✸	✸	✸
33	B-CELL / igE	ANTAGONISTS	✸	✸		✸	✸	✸	✸		
34	GLIAL CELL ACTIVATION / SCARRING	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸

Copyright : Vedicinals India Private Limited

CLINICAL TRIAL RESULTS OF VEDICINALS-9 ADJUVANT TREATMENT OF COVID19 PATIENTS & LONG COVID PREVENTION

HYPERINFLAMMATION



Human Clinical Trial Results of VEDICINALS 9
(Publication currently in journal peer review)



Human Clinical Trial Results of VEDICINALS 9
(Publication currently in journal peer review)



Human Clinical Trial Results of VEDICINALS 9
(Publication currently in journal peer review)

Copyright : Vedicinals India Private Limited

CLINICAL TRIAL RESULTS OF VEDICINALS-9 ADJUVANT TREATMENT OF COVID19 PATIENTS & LONG COVID PREVENTION

PHASE – 5 : ORGAN DAMAGE LUNG ABNORMALITIES



Human Clinical Trial Results of VEDICINALS 9
(Publication currently in journal peer review)

RESTORING LUNG FUNCTION AND PREVENTING FIBROSIS

Copyright : Vedicinals India Private Limited

CLINICAL TRIAL RESULTS OF VEDICINALS-9 ADJUVANT TREATMENT OF COVID19 PATIENTS & LONG COVID PREVENTION



MUSCLE PAIN / MUSCLE DAMAGE



Human Clinical Trial Results of VEDICINALS 9

Creatine phosphokinase
(a.k.a., creatine kinase, CPK, or CK)

- Is an enzyme (a protein that helps to elicit chemical changes in your body) found in your heart, brain, and skeletal muscles.
- When muscle tissue is damaged, CPK leaks into your blood.

Copyright : Vedicinals India Private Limited

CLINICAL TRIAL RESULTS OF VEDICINALS-9 ADJUVANT TREATMENT OF COVID19 PATIENTS & LONG COVID PREVENTION

PHASE - 4 : HYPERCOAGULATION / THROMBOSIS

Lowering Hypercoagulability





Human Clinical Trial Results of VEDICINALS 9 (Publication currently in journal peer review)

A

Possible Drug target pathways to prevent Thrombosis:

- Pdi inhibitors,
- P-selectin inhibitors,
- Lower platelet accumulation in arteries,
- Lower fibrin formation in veins,
- Inhibit enzymatic activity of thrombin,
- Coagulation factor x inhibitors,
- Ppi kinases inhibitors,
- Platelet cytosolic phospholipase inhibitors,
- Thromboxane a2 inhibitors,
- Emmprin/cd147 inhibitors

B

Restoring RBC plasticity/deformability

Copyright : Vedicinals India Private Limited

CLINICAL TRIAL RESULTS OF VEDICINALS-9 ADJUVANT TREATMENT OF COVID19 PATIENTS & LONG COVID PREVENTION



Time in allaying symptoms in % of days of treatment



Time in allaying symptoms in % of days of treatment

Copyright : Vedicinals India Private Limited

CLINICAL TRIAL RESULTS OF VEDICINALS-9 ADJUVANT TREATMENT OF COVID19 PATIENTS & LONG COVID PREVENTION



Time in allaying symptoms in % of days of treatment



Time in allaying symptoms in % of days of treatment

Copyright : Vedicinals India Private Limited

PRECLINICAL TRIAL RESULTS ON MYOCARDIAL INFARCTION



Objective

The objective of the study is to assess the effect of pre and post treatment of Vedinical-9 in isoproterenol induced myocardial infarction in rats

Copyright : Vedicinals India Private Limited

BIO-AVAILABILITY & ABSORPTION

Glutamate Pyruvate Transaminase (GPT) in blood serum.
GPT is an enzyme found in heart cells, kidney, muscles and liver



- Control /un-treated group GPT 135.4
- Conventional Supplements , 9 molecules combined GPT is 133.3
- Vedicinals – 9 treated group GPT 89.5

Improvement in GPT with

- Conventional 9 supplements administered mixed is 2.07
- Vedicinals- 9 is 45.8

21-fold increase in Bioavailability achieved by Vedicinals- 9 Suspension with proprietary knowhow

Copyright : Vedicinals India Private Limited

PRECLINICAL TRIAL RESULTS ON MYOCARDIAL INFARCTION



A troponin test measures the levels of troponin T or troponin I proteins in the blood. These proteins are released when the heart muscle has been damaged, such as occurs with a heart attack. The more damage there is to the heart, the greater the amount of troponin T and I there will be in the blood.

Copyright : Vedicinals India Private Limited

RESULTS
HISTOPATHOLOGY

Isoproterenol + Vedicinals-9 Formulation



Group 1: Isoproterenol –Mild myocardial degeneration, infiltration of inflammatory cells, and extra-vasated RBCs. H &E, 40X



Group 3: Isoproterenol+Vedicinal-9 bioenhanced –Minimal myocardial degeneration, No infiltration of inflammatory cells, and No hemorrhages or vacuolations seen. H &E, 40X

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE – 3 : HYPERINFLAMATION			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
35	INTERLEUKIN – 6	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
36	PRO-INFLAMMATORY CYTOKINE	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
36	TNF ALPHA	ANTAGONISTS	✸	✸	✸	✸		✸	✸	✸	✸
37	Nrf2	AGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	
38	NLRP-3 & CASPASE-1	ANTAGONISTS	✸	✸	✸		✸	✸	✸	✸	✸
39	STAT 3 PHOSPHORYLATION	ANTAGONISTS	✸	✸	✸			✸	✸	✸	✸
40	C REACTIVE PROTEIN	ANTAGONISTS	✸	✸		✸		✸	✸		✸
41	COX-2	ANTAGONISTS	✸	✸		✸	✸	✸	✸	✸	✸
42	CDK-6	ANTAGONISTS	✸	✸				✸	✸		
43	ROS	ANTAGONISTS	✸		✸		✸		✸		
44	EOSONOPHIL ACTIVATION	ANTAGONISTS	✸	✸	✸	✸		✸	✸		✸
45	NEUTROPHIL / NETOSIS	ANTAGONISTS	✸	✸	✸			✸	✸		
46	SPLA2 – IIA	ANTAGONISTS	✸	✸		✸		✸			✸
47	ANGIOTENSIN - II	ANTAGONISTS	✸	✸	✸			✸	✸		✸

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE – 3 : HYPERINFLAMATION			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
48	VITAMIN D RECEPTORS	AGONISTS		✸				✸			
49	PEROXYNITRITE	ANTAGONISTS	✸	✸		✸	✸	✸	✸		✸
50	INTRACELLULAR CALCIUM	ANTAGONISTS	✸	✸	✸		✸	✸	✸		
51	HEPCIDIN	ANTAGONISTS		✸				✸	✸		
52	LPS - INFLAMMATION	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
53	NF-KB	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
54	TLR4	ANTAGONISTS	✸	✸	✸		✸	✸	✸		

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

DRUG TARGET PATHWAYS - LONG HAULER INDEX			Active Ingredients								
COVID LONG HAULER PANEL - CH CYTOKINE 14 PANEL			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
55	TNF-ALPHA	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
56	IL-4	ANTAGONISTS	✸	✸	✸		✸	✸	✸	✸	✸
57	IL-13	ANTAGONISTS		✸	✸		✸	✸			✸
58	IL-2	ANTAGONISTS		✸	✸		✸	✸	✸	✸	
59	GM-CSF	ANTAGONISTS						✸	✸	✸	
60	SCD40L	ANTAGONISTS		✸	✸			✸	✸		
61	CCL5 RANTES	ANTAGONISTS	✸	✸	✸	✸		✸	✸	✸	✸
62	CCL3 MIP-1 ALPHA	ANTAGONISTS		✸				✸			
63	IL-6	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
64	IL-7	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	
65	IL-10	ANTAGONISTS		✸		✸					✸
66	IFN-GAMMA	ANTAGONISTS	✸	✸		✸	✸	✸	✸	✸	
67	VEGF	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
68	IL-8	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
69	CCL4 MIP-1 BETA	ANTAGONISTS	✸	✸	✸			✸	✸		

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE – 4 : HYPERCOAGULABILITY (THROMBOSIS)			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
70	THROMBIN	ANTAGONISTS	✸	✸	✸	✸		✸			✸
71	PLATELET AGGREGATION	ANTAGONISTS	✸	✸		✸		✸	✸	✸	✸
72	aPTT + PT PROLONGATION		✸	✸	✸	✸		✸			
73	FIBRIN FORMATION	ANTAGONISTS	✸			✸		✸			
74	D - DIMER	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
75	P - SELECTIN	ANTAGONISTS	✸	✸					✸		
76	RRC PLASTICITY / DEFORMABLITY	AGONISTS	✸	✸	✸	✸	✸	✸	✸		✸
77	PROTEIN DISULFIDE ISOMERASES	ANTAGONISTS		✸				✸			
78	ICAM1	ANTAGONISTS	✸	✸	✸		✸	✸	✸	✸	✸
79	VCAM1	ANTAGONISTS	✸	✸	✸		✸	✸	✸		

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE –5 : ORGAN DAMAGE (CYTOPROTECTIVE AND ORGAN RESTORING PATHWAYS)		Active Ingredients								
		BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
80	PROTECTING + RESTORING LUNG TISSUES	✸	✸		✸	✸	✸	✸	✸	✸
81	PROTECTING + RESTORING MYOCARDIAL TISSUES	✸	✸	✸	✸	✸	✸	✸	✸	
82	TROPONIN –L ANTAGONISTS (MYOCARDIAL DAMAGE)	✸	✸			✸	✸			
83	CREATINE KINASE ANTAGONISTS (MUSCLE DAMAGE)	✸	✸			✸	✸	✸		✸
84	PROTECTING + RESTORING CARDIOVASCULAR TISSUES	✸	✸	✸	✸	✸	✸	✸	✸	✸
85	HIF –1 ALPHA ANTAGONISTS (CARDIOVASCULAR MARKER)	✸	✸			✸	✸	✸		
86	PPAR GAMMA AGONISTS (CARDIOVASCULAR MARKER)		✸		✸	✸	✸		✸	
87	PROTECTING AGAINST CARDIAC FIBROSIS	✸	✸		✸	✸	✸	✸		
88	PROTECTING + RESTORING KIDNEY TISSUES	✸	✸	✸	✸	✸	✸	✸	✸	✸
89	PROTECTING + RESTORING LIVER TISSUES	✸	✸	✸			✸	✸		✸
90	PROTECTING + RESTORING PANCREATIC BETA CELLS	✸		✸		✸	✸	✸		
91	PROTECTING AGAINST INTESTINAL INFLAMMATION	✸	✸	✸	✸			✸		
92	PROTECTING GUT BACTERIA	✸	✸		✸	✸	✸	✸	✸	✸
93	PROTECTING + RESTORING TIGHT JUNCTIONS	✸	✸	✸	✸	✸	✸	✸	✸	✸
94	SENOLYTIC COMPOUND	✸	✸		✸	✸	✸	✸	✸	✸
95	HEME OXYGENASE AGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE –5 : ORGAN DAMAGE (CYTOPROTECTIVE AND ORGAN RESTORING PATHWAYS)			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
96	CREATIN KINASE CK	ANTAGONISTS	✸	✸			✸	✸	✸		✸
97	BRCA1	AGONISTS		✸				✸			
98	P53	AGONISTS		✸	✸	✸	✸	✸	✸	✸	
99	SIRT1	AGONISTS	✸	✸	✸			✸	✸		✸
100	PTX3	ANTAGONISTS	✸				✸	✸	✸		
101	GLYCOCALYX	PROTECTION		✸					✸		
102	TOXIN LIKE PEPTIDES (GUT)	ANTAGONISTS									

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE –5 : NEURONAL DAMAGE (CYTOPROTECTIVE PATHWAYS)			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
103	NEURO-PROTECTVE + ANTI NEURO-INFLAMMATORY AGENTS		✸	✸	✸	✸	✸	✸	✸	✸	✸
104	PROTECTING + RESTORING MYELIN SHEATH		✸	✸			✸	✸	✸		✸
105	NEUROGENESIS + SYNAPTOGENESIS	AGONISTS	✸	✸			✸	✸	✸		
106	ENCEPHALOMYELITIS	ANTAGONISTS	✸	✸	✸				✸		✸
107	PRION FORMATION PrPC	ANTAGONISTS	✸	✸				✸	✸		
108	ALPHA SYNUCLEIN /LEWY BODIES	ANTAGONISTS	✸	✸		✸		✸	✸		
109	MYOSIN + FILOPODIA ADHESION	ANTAGONISTS	✸		✸				✸	✸	
110	TDP - 43	ANTAGONISTS							✸	✸	
111	TAU PROTIEN AGGREGATION (HEPARIN BINDING)	ANTAGONISTS	✸	✸	✸	✸		✸	✸		
112	AMYLOID AGGREGATION	ANTAGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	
113	CASEIN KINASE - 2	ANTAGONISTS	✸	✸	✸				✸		✸
114	GLUTATHIONE	AGONISTS	✸	✸		✸	✸	✸	✸		
115	BDNF	AGONISTS	✸	✸	✸	✸	✸	✸	✸	✸	✸
116	PROTECTING + RESTORING MITOCHONDRIAL FUNCTION		✸	✸	✸		✸	✸	✸	✸	✸
117	PREVENTING AUTOIMMUNE DYSFUNCTION			✸		✸		✸	✸		
118	PROTECTING + RESTORING BBB INTEGRITY		✸	✸		✸	✸	✸			

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE –5 : NEURONAL DAMAGE (CYTOPROTECTIVE PATHWAYS)			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
119	CYTOCHROME C	ANTAGONISTS	✸	✸	✸			✸	✸		
120	TRPV1	DESENSITISATION	✸	✸				✸	✸	✸	
121	CD38	INHIBITORS		✸	✸						
122	NAD+										
123	KVNURENINE/TRYPTOPHANE	BALANCE	✸	✸	✸		✸	✸	✸		✸
124	QUINOLINIC ACID	ANTAGONISTS						✸	✸		
125	EXOSOME SHEDDING	ANTAGONISTS	✸	✸				✸	✸		
126	REDOX	BALANCE	✸	✸	✸	✸		✸	✸		✸
127	OXPHOS	REGULATION	✸	✸				✸			
128	HPA/HTPA AXIS	BALANCE	✸	✸			✸	✸	✸	✸	✸
129	GREY MATTER/ WHITE MATTER VOLUME	PROTECTION		✸				✸	✸		
130	TOM70										

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

PHASE - 6 : METABOLIC DISORDERS			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
131	HYPERGLYEMIA	ANTAGONISTS	✸	✸	✸				✸		
132	ALPHA - GLUCOSIDASE + AMYLASE	ANTAGONISTS	✸	✸	✸	✸		✸	✸	✸	✸
133	HYPERLIPIDEMIA	ANTAGONISTS	✸	✸		✸		✸	✸	✸	✸
134	GLYCOLYSIS + GLUTAMINOLYSIS	ANTAGONISTS		✸	✸			✸	✸	✸	

IMMUNO MODULATING PATHWAYS			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
135	T - CELL STABLIZERS TH1 / TH2 BALANCE		✸	✸				✸	✸		✸
136	BACTERIAL CO-INFECTION & BIOFILM		✸	✸	✸	✸		✸	✸	✸	✸
137	mTOR	INHIBITORS	✸	✸	✸	✸	✸	✸	✸	✸	✸
138	MACROPHAGE POLARISATION + CCLZ REGULATORS	ANTAGONISTS	✸	✸	✸	✸		✸	✸		✸
139	CCRS	ANTAGONISTS	✸	✸	✸				✸		
140	CX3CR1 FRAKTALKINE	ANTAGONISTS	✸				✸	✸	✸		

Copyright : Vedicinals India Private Limited

Comprehensive Nutraceutical Interventions For (LONG)COVID 19 Conditions

SECONDARY INFECTIONS/ PATHOGENIC OVERGROWTH			Active Ingredients								
			BAICALIN	QUERCETIN	LUTEOLIN	RUTIN	HESPERIDIN	CURCUMIN	EGCG	PIPERINE	GLYCYRRHIZIN
141	BACTERIAL COINFECTIONS (VARIOUS)	INHIBITORS	✸	✸	✸	✸	✸	✸	✸	✸	✸
142	LYME BORRELIOSIS	INHIBITORS	✸	✸	✸						
143	MULTIDRUG RESISTANT BACTERIA	INHIBITORS	✸	✸	✸	✸	✸	✸	✸	✸	✸
144	BIOFILM	INHIBITORS + DEGRADATION	✸	✸	✸		✸		✸	✸	✸
145	CANDIDA & OTHER FUNGI	INHIBITORS	✸	✸	✸	✸		✸	✸	✸	✸
146	REVERSE TRANSCRIPTASE INHIBITORS	INHIBITORS	✸	✸	✸	✸	✸	✸	✸		✸
147	(32) EPSTEIN-BARR	INHIBITORS	✸	✸	✸			✸	✸		✸
148	HERPES SIMPLEX TYPE 1	INHIBITORS	✸	✸				✸	✸		✸
149	RSV	INHIBITORS	✸	✸	✸	✸	✸	✸	✸		✸
150	CYTOMEGALOVIRUS	INHIBITORS	✸	✸				✸	✸		✸

Copyright : Vedicinals India Private Limited

28 DAYS REPEATED DOSE TOXICITY STUDY IN SPRAGUE DAWLEY RATS.

PRADO
advance the safety evaluation

Study Report for Study No.: PRADO/TOX-261

SUMMARY

Study No.	PRADO/TOX-261
Test Item	CORONASH™
Study Title	28 Days Repeated Dose Toxicity Study of CORONASH™ by Oral Route in Sprague Dawley Rat with 14 Days Recovery Period
Route	Oral
Dose	Vehicle (0 mg/kg/day) and CORONASH™ (500, 750, 1000 mg/kg)
No. of Groups	6 (6 Animals/Sex/Group)

Parameters were evaluated include mortality, clinical signs, detailed clinical examination, body weight, feed consumption, Ophthalmoscopic examination, hematology, clinical chemistry, urine analysis, organ weights, gross and histopathological examination.

All the animals survived till the scheduled necropsy. All animals well tolerated the oral dose of **CORONASH™** up to 1000 mg/kg for 28 consecutive days without any apparent signs of toxicity.

Weekly detailed clinical examinations did not reveal any clinical abnormalities in any of the animals. No treatment related adverse effects were noticed during ophthalmic examination at 1000 mg/kg in both sexes.

No test item related adverse effects were observed in body weights during experiment period. Feed consumption in all treatment groups was comparable with respective control groups.

There were no test item related gross pathological changes observed up to 1000 mg/kg in both sexes at the end of treatment and recovery period. There was no test item-related histopathological changes observed at high dose of 1000 mg/kg dose in both sexes at the end of treatment period.

All animals well tolerated the oral doses of **CORONASH™** up to and including 1000 mg/kg for 28 consecutive days without any toxic effects. The NOAEL for **CORONASH™** is considered to be 1000 mg/kg in both sexes after 28 days repeated oral administration in Sprague Dawley rats under above study conditions.

Please Note : In early 2020 a working title **CORONASH™** was being used, it is referring to the same product as later renamed VEDICINALS-9.

Copyright : Vedicinals India Private Limited

ACUTE TOXICITY STUDY IN SPRAGUE DAWLEY RATS.

PRADO

Study Report for Study No.-PRADO/TOX-260

SUMMARY

Study No.	PRADO/TOX-260
Test Item	CORONASH™
Study	Acute Toxicity Study in Rats
Route	Oral
Dose	2000 mg/kg
No. of Groups	2 (3 Females/Group)

Based on the results of this study, i.e. 'Acute Toxicity Study of **CORONASH™** by Oral Route in Sprague Dawley Rats', the Median Lethal Dose (LDso) of CORONASIM upon a single oral administration to female Sprague Dawley rats, in accordance with Globally Harmonized Classification System is **Category 5 (>5000 mg/kg of body weight).**

- **The LDso cut off value is 5000 mg/kg of body weight.**
- **Globally Harmonized Classification and Labelling of Chemicals: Category 5.**
- **For Restricted Circulation Only**

Please Note : In early 2020 a working title **CORONASH™** was being used, it is referring to the same product as later renamed VEDICINALS-9.

Copyright : Vedicinals India Private Limited

Adverse Event Reports Of Human Clinical Trials.

12.2 ADVERSE EVENTS

12.2.1 Summary of adverse events

- No AE recorded.
- No summary listed.

12.2.2 Display of adverse events

- One non-serious event (Headache) was reported by the one patient who was randomized to standard treatment (Appendix 16.3.1).
- The reported event of headache was mild in severity and was not related to the study medication (Appendix 16.3.1).

12.2.4 Listing of adverse events by patient
No AE listing was generated as there was only one non-serious event headache reported.

12.3 DEATHS, OTHER SERIOUS ADVERSE EVENTS AND OTHER SIGNIFICANT ADVERSE EVENTS

- There were no deaths, serious adverse events and other significant adverse events reported in the study. Therefore, no listings were generated, and no narratives were required.

12.3.1 Listing of Deaths, other Serious Adverse Events and Other Significant Adverse Events

Copyright : Vedicinals India Private Limited

QUALITY CONTROL DATA, HPLC, CHROMATOGRAMS, HEAVY METAL ANALYSIS

TIRUPATI MEDICARE LTD.

Nahan Road, Poanta Sahib, Distt. Sirmour, HP

Summary(Compound)



<< PDA >>

ID#1 Compound Name: Quercetin

Title	Sample Name	Sample ID	Ret. Time	Area	Tailing Factor	NTP
04.12.2020_Immunity_Assay	Immunity Booster	S/SCL/20001_1M_40/75_02	12.614	3088386	1.088	49247
04.12.2020_Immunity_Assay	Immunity Booster	S/SCL/20001_1M_40/75_01	12.614	3117387	1.096	48724
Average			12.614	3102887	1.092	48985
%RSD			0.000	0.661	0.496	0.755
Maximum			12.614	3117387	1.096	49247
Minimum			12.614	3088386	1.088	48724
Standard Deviation			0.000	20507	0.005	370

ID#2 Compound Name: Lectolein

Title	Sample Name	Sample ID	Ret. Time	Area	Tailing Factor	NTP
04.12.2020_Immunity_Assay	Immunity Booster	S/SCL/20001_1M_40/75_02	13.389	5446253	1.122	45409
04.12.2020_Immunity_Assay	Immunity Booster	S/SCL/20001_1M_40/75_01	13.390	5423991	1.121	45251
Average			13.390	5435122	1.122	45330
%RSD			0.003	0.290	0.082	0.247
Maximum			13.390	5446253	1.122	45409
Minimum			13.389	5423991	1.121	45251
Standard Deviation			0.000	15741	0.001	112

Dove Research & Analytics

(A unit of Dove Chemicals Ltd.)

A Govt. Approved GLP Certified, and FSSAI Approved Laboratory

Test Report

A.R. No. : DA/FP-150221/031

1. SAMPLE SENT BY: **TIRUPATI MEDICARE LIMITED PAONTA SAHIB, SIRMOUR.** 2.Reference No.: **N.M.**

3. SAMPLE RECEIVED ON: **15/02/2021** 4. NAME OF SAMPLE: **VEDICINALS -9**

5. Detail of ~~Raw materisl~~/ final product ~~(in bulk/finished pack)~~

(a) Manufactured by: N.M. (b) Batch No.: **S/SCL/20001 (3 MLT)**

(c) Mfg. Lic. No.: N.M.

(d) Sample Qty. 2 bottles (e) B. Size: N.M.

(f) D/M: N.M. (g) D/E: N.M.

6. Analysis Started On : **19/02/2021** 7. Analysis Completion On: **20/02/2021**

8. Date of Amendment: N.A

9. Protocol of test applied: As per customer specification

Description: Light brown viscous liquid.

TEST PARAMETERS	OBTAINED	LIMIT
Heavy Metals (by ICP-OES)		
Lead	Not Detected	NMT 1.00 ppm
Mercury	Not Detected	NMT 1.00 ppm
Arsenic	Not Detected	NMT 0.500 ppm
Cadmium	Not Detected	NMT 0.500 ppm

In the opinion of the undersigned, the sample referred to above is of Standard Quality / ~~is not of Standard Quality~~ as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s)mentioned above.

THE SAMPLE CONFORMS WITH RESPECT TO CUSTOMER SPECIFICATION

----------End of Report----------

(Add. Person Incharge)

Authorised Signatory

Note. 1. The result listed refers only to the tested samples & applicable parameters; endorsement of products is neither inferred nor implied.
2. Our liability is limited to invoiced amount
3. This report is not to be reproduced wholly or in part and cannot be used as evidence in the court of law and should not be used in any advertising media without our special permission in writing.
4. Sample drawn and submitted by the party for Analysis unless otherwise stated.

OUR MISSION : OUR AIM IS TO BECOME THE MOST ECONOMICAL, EFFICIENT & RELIABLE TESTING FACILITY FOR DRUGS, WATER & FOOD.

Plot No. : 298, Industrial Area, Phase II, Panchkula - 134 109 (Haryana)
Tel. : +91-172-2595298, 5010126 E-mail : drachd@gmail.com
URL : www.doveresearchlab.com

Copyright : Vedicinals India Private Limited

VEDICINALS 9®

BAICALIN	352mg
QUERCETIN	100mg
LUTEOLIN	200mg
RUTIN	736mg
HESPERIDIN	667mg
CURCUMIN	1052mg
EPIGALLOCATECHIN-GALLATE	889mg
PIPERINE	15mg
GLYCYRRHIZIN	505mg

Suspension 50 mL

Recommended Dosage :

01 Bottle (50mL) Daily for 28 days or 42 days as directed by your medical professional.

"We want to thank your members for all efforts to provide (early) treatment and placing the patient's well-being above all other interest! "

Q & A

Ordering outside India
www.vedicinals-international.com/product/vedicinals-9

For ordering within India:
https://www.vedicinals.com/product/vedicinals-9/

Disclaimer : This presentation cannot and does not contain medical advice. The information is provided for general informational and educational purposes only and is not a substitute for professional medical advice. Accordingly, before taking any actions based upon such information, we encourage you to consult with the appropriate professionals. We do not provide any kind of medical advice.

Copyright : Vedicinals India Private Limited

VEJON CONFERENCES

Long Covid Coalition Conference

Saturday 30th April, 2022 @ 13:00 ET / 18:00 UK time

SPEAKER 1

Dr Carlo Brogna
Italy

SPEAKER 2

Dr Michael Van Elzakker
USA

SPEAKER 3

Dr Leo Galland
USA

Stephanie Seneff, PhD
USA

Joachim Gerlach
Germany

Dr Shankara Chetty
South Africa

Dr Abdul Mannan Baig
Pakistan

Valentina Viduto, PhD
UK

Dr Philip McMillan
UK

PANELISTS